WALVAX(300142)2023-10-25 16:00Financial Performance - Total revenue for Q3 2023 was ¥990,373,049.55, a decrease of 27.08% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥98,136,640.53, down 11.10% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥135,818,292.29, a decline of 30.93% compared to the previous year[3]. - The basic earnings per share for Q3 2023 was ¥0.0613, down 12.55% from the same period last year[3]. - In Q3 2023, the company's net profit reached CNY 697,229,401.89, a slight increase from CNY 688,704,070.22 in Q3 2022, representing a growth of approximately 0.76%[44]. - The total profit for the period was CNY 774,221,056.21, down from CNY 805,801,337.87 in the same quarter last year, a decrease of approximately 3.93%[44]. Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥15,591,153,946.03, an increase of 1.72% from the end of the previous year[4]. - The equity attributable to shareholders increased by 5.15% to ¥9,551,615,624.59 compared to the end of the previous year[4]. - Total liabilities decreased to CNY 3,989,889,620.16 from CNY 4,346,230,903.43, a reduction of approximately 8.21%[42]. - The company's total assets reached CNY 15,591,153,946.03, compared to CNY 15,336,026,444.93, marking an increase of about 1.67%[42]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥860,936,364.22, a slight decrease of 1.19% year-on-year[3]. - The net cash flow from operating activities for the current period is ¥86,093.63 million, a decrease of 1.19% compared to the previous period's ¥87,126.20 million, primarily due to increased sales returns from vaccine products by ¥39,048.26 million and increased operational expenses by ¥40,080.82 million[11]. - The cash flow from investing activities resulted in a net outflow of CNY 574,228,118.23, an improvement compared to the outflow of CNY 829,400,049.68 in the previous year[45]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 128,384, with the top ten shareholders holding a combined 13.72% of the shares[12]. - Liu Junhui, the largest shareholder, holds 3.37% of the shares, amounting to 54,161,648 shares[12]. - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 3.30% of the shares, totaling 53,010,622 shares[12]. - The company has a total of 39,823,007 restricted shares held by executives, which remain locked under a 75% annual restriction policy[14]. Vaccine Sales and Development - The company reported a significant decrease in vaccine product sales, contributing to a 14.79% decline in revenue year-to-date[9]. - The company achieved a total of 28,781,764 vaccine doses approved for sale from January to September 2023, representing a year-on-year increase of 98.18%[17]. - The 13-valent pneumococcal conjugate vaccine saw a slight decrease in approved doses to 5,795,158, down 4.50% from the previous year, while the bivalent HPV vaccine increased by 127.61% to 4,753,645 doses[18]. - The company has successfully established a mature bacterial vaccine technology platform and a recombinant protein vaccine technology platform, and is developing mRNA and recombinant adenovirus vaccine technology platforms[16]. - The company is advancing the phase III clinical trials for the ACYW135 meningococcal polysaccharide conjugate vaccine and the nine-valent HPV vaccine[19]. International Business - The company has made significant progress in international business, exporting products to 18 countries, covering Southeast Asia, South Asia, Central Asia, Africa, and the Americas[22]. - The company received procurement orders for the 13-valent pneumococcal conjugate vaccine from Morocco and completed product delivery during the reporting period[23]. - The 13-valent pneumococcal conjugate vaccine obtained approval for a Phase III clinical trial in Indonesia, marking a key milestone in the company's international strategy[23]. - The company is actively pursuing WHO pre-qualification for its bivalent HPV vaccine and ACYW135 meningococcal polysaccharide vaccine[23]. Stock Options and Repurchase - The company approved the cancellation of 1.15 million stock options granted to two departing employees from the 2018 stock option incentive plan, reducing the number of initial grant recipients to 197 and the total number of options to 57.5 million[26]. - The company plans to repurchase up to 4 million shares, representing 0.25% of total share capital, with a maximum repurchase price of RMB 49.99 per share[34]. - As of the report date, the company has repurchased 2 million shares at an average price between RMB 35.69 and RMB 36.28, totaling approximately RMB 72.2 million[35]. Research and Development - Research and development expenses decreased to CNY 573,442,296.50 from CNY 677,337,642.55, reflecting a reduction of approximately 15.36%[44]. - The company aims to enhance its product pipeline and technological capabilities through continuous innovation in vaccine development[20]. Miscellaneous - The third quarter report was not audited[49].